Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses.
Article Details
- CitationCopy to clipboard
Bressolle F, Costa P, Rouzier-Panis R, Marquer C
Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses.
Eur J Clin Pharmacol. 1996;49(5):411-5.
- PubMed ID
- 8866639 [ View in PubMed]
- Abstract
OBJECTIVE: The concentration-time profiles of specific metabolites of moxisylyte, an alpha-adrenoceptor blocking agent, in the plasma and urine from 18 healthy volunteers were investigated after intracavernous (IC) administrations at three dose levels (10, 20 and 30 mg). RESULTS: Four metabolites, unconjugated desacetyl-moxisylyte (DAM), DAM glucuronide, and DAM and monodesmethylated DAM (MDAM) sulphates were found in plasma and urine. For all metabolites, t1/2 elimination was independent of the administered dose (1.19 h for unconjugated DAM; 1.51 h for DAM glucuronide; 1.51 h for DAM sulphate; and 2.17 h for MDAM sulphate). Cmax and AUC increased in direct proportion to dose, except for the inactive DAM glucuronide. Any the differences detected were small and equivalence of the three doses can be accepted. CONCLUSION: The pharmacokinetics of moxisylyte in humans following intracavernous administration were linear in the dose range 10 to 30 mg.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Moxisylyte Cholinesterase Protein Humans NoSubstrateDetails - Drug Reactions
Reaction Details Details Details Details Details
